| Title: |
Investigation of molecular design, synthesis, and biological assessment of new benzopyran derivatives |
| Authors: |
Mahesh Agasa Ramu, Somashekhar Metri, Trupti A Hunnura, Koushallya Patil, Hanamant B Sannakki |
| Source: |
Journal of Applied Pharmaceutical Research, Vol 13, Iss 1, Pp 86-94 (2025) |
| Publisher Information: |
Creative Pharma Assent, 2025. |
| Publication Year: |
2025 |
| Collection: |
LCC:Pharmacy and materia medica
LCC:Therapeutics. Pharmacology |
| Subject Terms: |
anti-tubercular compounds, pks13 (pdb id: 5v3y), molecular docking, benzopyran derivatives, alamar blue susceptibility assay (maba), Pharmacy and materia medica, RS1-441, Therapeutics. Pharmacology, RM1-950 |
| More Details: |
Background: Tuberculosis (TB) remains a global health challenge, necessitating the discovery of novel anti-tubercular agents. The N-(8-hydrazinyl-3,4-dihydro-2H-1-benzopyran-6-yl)-N'-phenyl urea (HSM-II) scaffold has shown potential in developing effective drug candidates. Objective: This study aimed to design and evaluate 50 derivatives of HSM-II for their anti-tubercular activity, focusing on compounds demonstrating strong interactions with the protein PKS13 (PDB ID: 5v3y). Methods: A series of derivatives was synthesized, starting with the reaction of 8-bromo-3,4-dihydro-2H-1-benzopyran-6-amine and phenyl carbamic acid, yielding six new benzopyran derivatives. These were further treated with various aromatic halides to produce the HSM-II derivatives. Molecular docking studies were performed to identify compounds with high binding affinity to PKS13. Promising candidates (HSM-II-3, HSM-II-13, HSM-II-27, HSM-II-33, HSM-II-42, and HSM-II-49) were selected for biological evaluation. Anti-tubercular activity was assessed in vitro using the Alamar Blue Susceptibility Test (MABA) against Mycobacterium tuberculosis H37Rv and H37Ra strains. Results: Docking studies revealed high binding scores for the selected compounds, indicating strong interactions with the target protein. In vitro evaluations demonstrated significant anti-tubercular activity for the majority of synthesized derivatives. The pharmacologic profile of the compounds suggests potential as lead candidates for further optimization. Conclusion: This study presents the design, synthesis, and biological evaluation of 50 diverse derivatives of N-(8-hydrazinyl-3,4-dihydro-2H-1-benzopyran-6-yl)-N'-phenyl urea (HSM-II). Six derivatives (HSM-II-3, HSM-II-13, HSM-II-27, HSM-II-33, HSM-II-42, and HSM-II-49) demonstrated high binding affinities with PKS13 (PDB ID: 5v3y), with scores reaching -11.4 kcal/mol, and potent in vitro anti-tubercular activity, as assessed using the Alamar Blue Susceptibility Assay (MABA). Prominent derivatives exhibited MIC values significantly lower than those of standard drugs like rifampicin. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2348-0335 |
| Relation: |
https://japtronline.com/index.php/joapr/article/view/722; https://doaj.org/toc/2348-0335 |
| DOI: |
10.69857/joapr.v13i1.722 |
| Access URL: |
https://doaj.org/article/caec5588d4a8436c97625f4de3c4c6a0 |
| Accession Number: |
edsdoj.5588d4a8436c97625f4de3c4c6a0 |
| Database: |
Directory of Open Access Journals |
